Nutritional and prognostic value of bioelectrical phase angle as a potentially modifiable marker in acute myeloid leukemia

作者全名："Jiang, Tiantian; Weng, Yue; Zhang, Nan; Tang, Xiaoqiong"

作者地址："[Jiang, Tiantian; Weng, Yue; Tang, Xiaoqiong] Chongqing Med Univ, Affiliated Hosp 1, Dept Hematol, 1 Youyi Rd, Chongqing 400016, Peoples R China; [Zhang, Nan] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, 1 Youyi Rd, Chongqing 400016, Peoples R China"

通信作者："Tang, XQ (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Hematol, 1 Youyi Rd, Chongqing 400016, Peoples R China.; Zhang, N (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, 1 Youyi Rd, Chongqing 400016, Peoples R China."

来源：EXPERIMENTAL AND THERAPEUTIC MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000941457400001

JCR分区：Q3

影响因子：2.4

年份：2023

卷号：25

期号：3

开始页：　

结束页：　

文献类型：Article

关键词：acute myeloid leukemia; chemotherapy; bioelectrical impedance analysis; phase angle; nutrition; survival

摘要："Phase angle (PhA), as measured by bioelectrical impedance analysis, is an important parameter in nutritional assessment and is highly predictive of clinical outcomes in various diseases; however, there is little research on its use in acute myeloid leukemia (AML). Therefore, the present study was conducted to determine the association between PhA and malnutrition and to clarify the prognostic significance of PhA for progression-free survival (PFS) and overall survival (OS) in adult patients with AML (excluding acute promyelocytic leukemia) who were undergoing chemotherapy. A total of 70 patients with newly diagnosed AML were enrolled. After chemotherapy, the nutritional risk for patients with a reduced baseline PhA increased significantly. Disease progression occurred in 28 patients, of which 23 died, with a median follow-up of 9.3 months. A reduced baseline PhA was associated with poor PFS (7.1 months vs. 11.6 months; P=0.001) and OS (8.2 months vs. 12.1 months; P=0.011). A multivariate analysis revealed that a reduced PhA was an independent risk factor for disease progression (hazard ratio, 3.13; 95% CI, 1.21-8.11; P=0.019). Overall, these results suggested that PhA is an effective and sensitive indicator that may provide important nutritional and prognostic information in patients with AML."

基金机构：　

基金资助正文：